Enzolytics Inc (ENZC)

[Timing101]

LET THIS SINK IN; THOUGHTs, Facts, TIMELINE
---
1. ENZC, prior to September 2020 on PR's was just Harry Z . Harry Z has been around for sometime and Harry by himself, was spinning his wheels. In Reality Work has been going on for sometime well past Harry
-
2. Starting in September (9/16/2020) ENZC rises like the "Phoenix" and now has had SIX STRONG PR's , Five Disclosures on OTC Markets (more to come) , moved to TEXAS (SEC Filing 4/16) , Moved to Wyoming SOS 5/21/20 and also Named a New CEO, NEW CSO (2 Harry and Joseph) and New COO Gaurav, updated their website and updated OTC Markets with new CEO.
Whoa all that in Two Months
--
3. All these shares have appeared (IMO I could be entirely wrong) from Charles Cotropia a 40 YEAR SUPER ATTORNEY in Patents, Corporate , Trademarks simply stating to Harry , I need to be the CEO in CHARGE and you need to clean up the shares you handed out prior to your European Connections (millions) and the ZHABILOV Trust . This is going to be US Company and Charles stated if you want us , then you will become the CSO with Joseph and those shares need to be converted . On top of that for the Restricted Shares to go up by 300 Million , those went to the New CEO, Directors and maybe Board Members.
Harry did this and is simply stated in his statement in the PR
Quote
"Harry Zhabilov CSO stated, "It has long been a dream of mine to be able to partner with an individual and management team such as BioClonetics to realize the full value of the Company's patented technology for ENZC and its shareholders.""
--
4. So we know Charles C had all or similar discussion prior to the First PR as he would never put his Name, Integrity and their groups decade on the line for just Harry Z . This has all be in the works since the SEC FILING (very important to know the difference between an SEC Filing and just OTC disclosures) on 4/16/2020. So Months in the works here folks.
--
5.11/10/2020 We know they were meeting with a GMP Manufacturer by the end of the Monday and what do you know Ronald Moss MD comes on board as Medical Advisor. Just so your know here is his salary last year at the Company he is Chief Medical officer for . Adamis Pharmaceuticals.
Ronald Moss Net Worth

The estimated Net Worth of Ronald B. Moss is at least $1.56 Million dollars as of 18 August 2020. . In addition, he makes $1,339,550 as Chief Medical Officer at Adamis Pharmaceuticals.
--
6. So Ronald Comes on to the MEDICAL ADVISORY BOARD, while still being Chief Medical Officer at Adamis. Wonder why he is making per Month the rate of $111,629.00 , not to shabby !!!
lets see what does Ronald specialize in https://www.linkedin.com/in/ronald-moss-18130212/
Quote
I trained in the Laboratory of Clinical Investigation at the National Institute of Allergy and Infectious Disease, National Institutes of Health. I have been involved in clinical trials and Company leadership for over thirty years. I am also a practicing physician. I have been fortunate to successfully work with KOL's including the late Dr. Jonas Salk. I have worked closely with FDA, WHO, CDC, and NIH. My focus has always been about the patient and evidenced based therapeutics and vaccines that advances public health.

My experience includes the execution of successful phase 1-3 trials in both pediatric and adult populations in the U.S. , Europe, Asia, Africa, and South America. I have been involved in multiple phase 1, phase 2 and phase 3 clinical trials including preventative and therapeutic vaccines, biologics, small molecules for COVID19. rheumatoid arthritis, asthma, multiple sclerosis, CMV, HIV, anaphylaxis and antivirals (influenza and parainfluenza). I have also been the lead for two successful vaccine BLA’s and two successful NDA's. I have led advisory panel meeting with both the FDA and EMEA. I have been involved in FAST Track, Orphan and Breakthrough Designations. As a physician I have a unique understanding of science, clinical niches, clinical operations, and regulatory strategy.

I am an author of over 100 peer reviewed publications and has given hundreds of presentations at key scientific and regulatory meetings. My publications include co-authors include the late Jonas Salk and Robert Gallo. I have held major management positions in biotechnology and pharmaceutical companies and has been involved with executing successful partnerships and fund raising including experience as a CEO and CMO. I have successfully completed private and public equity raises including NIH and BARDA funding.
"

Just as a reminder folks we are moving very fast, but this has been in the works for Months... I's dotted, T's Crossed, SuperBowl Team put together over that time .
----
News PR's...
--
https://www.otcmarkets.com/stock/ENZC/news
*
Enzolytics, Inc. Appoints Ronald Moss, M.D. to Its Medical Advisory BoardACCESSWIRE | 11/10/2020
Enzolytics, Inc. Announces Appointment of Charles Cotropia as CEO of ENZC and Harry Zhabilov as Its CSOACCESSWIRE | 10/22/2020
Enzolytics, Inc. Shares BioClonetics Immunotherapeutics, Inc. Company UpdateACCESSWIRE | 10/19/2020
Enzolytics, Inc. Announces Execution of Binding Letter of Intent for Merger with BioClonetics Immunotherapeutics, Inc.ACCESSWIRE | 10/14/2020
Enzolytics, Inc. Announces New Board Member, Charles Cotropia, CEO of BioClonetics Immunotherapeutics, Inc. Harry Zhabilov CEO of Enzolytics to Join Board of BioCloneticsACCESSWIRE | 10/01/2020
Enzolytics, Inc. Announces Execution of Letter of Intent with BioClonetics Immunotherapeutics, Inc. (With Additional Update on 2020 Initiatives)ACCESSWIRE | 09/16/2020
Displaying 6 of 6 News Listings